Toshihisa Kojima1, Yuichiro Yabe2, Atsushi Kaneko2, Nobunori Takahashi2, Koji Funahashi2, Daizo Kato2, Masahiro Hanabayashi2, Shuji Asai2, Shinya Hirabara2, Nobuyuki Asai2, Yuji Hirano2, Masatoshi Hayashi2, Hiroyuki Miyake2, Masayo Kojima2, Naoki Ishiguro3. 1. Department of Orthopaedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Department of Rheumatology, JCHO Tokyo Shinjyuku Medical Center, Tokyo, Department of Orthopaedic Surgery, Nagoya Medical Centre, Nagoya, Department of Public Health, Nagoya City University Graduate School of Medical Sciences, Department of Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Department of Rheumatology, Nagano Red Cross Hospital, Nagano, Department of Orthopaedic Surgery, Ichinomiya Municipal Hospital, Ichinomiya and Department of Orthopaedic Surgery, Nagoya University, Faculty and Graduate School of Medicine, Nagoya, Japan. toshik@med.nagoya-u.ac.jp. 2. Department of Orthopaedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Department of Rheumatology, JCHO Tokyo Shinjyuku Medical Center, Tokyo, Department of Orthopaedic Surgery, Nagoya Medical Centre, Nagoya, Department of Public Health, Nagoya City University Graduate School of Medical Sciences, Department of Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Department of Rheumatology, Nagano Red Cross Hospital, Nagano, Department of Orthopaedic Surgery, Ichinomiya Municipal Hospital, Ichinomiya and Department of Orthopaedic Surgery, Nagoya University, Faculty and Graduate School of Medicine, Nagoya, Japan. 3. Department of Orthopaedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Department of Rheumatology, JCHO Tokyo Shinjyuku Medical Center, Tokyo, Department of Orthopaedic Surgery, Nagoya Medical Centre, Nagoya, Department of Public Health, Nagoya City University Graduate School of Medical Sciences, Department of Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Department of Rheumatology, Nagano Red Cross Hospital, Nagano, Department of Orthopaedic Surgery, Ichinomiya Municipal Hospital, Ichinomiya and Department of Orthopaedic Surgery, Nagoya University, Faculty and Graduate School of Medicine, Nagoya, Japan. Department of Orthopaedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Department of Rheumatology, JCHO Tokyo Shinjyuku Medical Center, Tokyo, Department of Orthopaedic Surgery, Nagoya Medical Centre, Nagoya, Department of Public Health, Nagoya City University Graduate School of Medical Sciences, Department of Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Department of Rheumatology, Nagano Red Cross Hospital, Nagano, Department of Orthopaedic Surgery, Ichinomiya Municipal Hospital, Ichinomiya and Department of Orthopaedic Surgery, Nagoya University, Faculty and Graduate School of Medicine, Nagoya, Japan.
Abstract
OBJECTIVE: The purpose of this study was to identify the effects of concomitant use of MTX and baseline characteristics for remission in the treatment of RA with tocilizumab (TCZ) in daily clinical practice. METHODS: A total of 240 RA patients who received TCZ were selected from the multicentre Tsurumai Biologics Communication Registry. Predictive baseline factors for remission [28-item DAS (DAS28) < 2.6] at 52 weeks were determined by logistic regression analysis. To confirm whether the associations varied by the level of baseline disease activity, we also assessed the model including the interaction term (each baseline variable × DAS28). RESULTS: In total, 49.3% of the study participants used MTX with TCZ. Even after controlling for the baseline DAS28, shorter disease duration (≤3 year) [odds ratio (OR) 3.58 (95% CI 1.81, 7.07)], less structural damage [Steinbroker stage ≤II, OR 2.33 (95% CI 1.32, 4.12)] and concomitant prednisolone use [OR 0.38 (95% CI 0.21, 0.68)] showed significant predictive values for remission. Concomitant MTX use failed to show a significant association with remission, whereas a significant interaction was observed among concomitant MTX use × DAS28 (P = 0.006). In patients with high baseline disease activity (DAS28 > 5.1), concomitant MTX use was associated with increased odds for remission [adjusted OR for all baseline variables 2.54 (95% CI 1.11, 5.83)], while no association was indicated between them in patients with low to moderate baseline disease activity (DAS28 ≤ 5.1). CONCLUSION: Concomitant MTX use is an important component of TCZ treatment for RA patients with high disease activity.
OBJECTIVE: The purpose of this study was to identify the effects of concomitant use of MTX and baseline characteristics for remission in the treatment of RA with tocilizumab (TCZ) in daily clinical practice. METHODS: A total of 240 RApatients who received TCZ were selected from the multicentre Tsurumai Biologics Communication Registry. Predictive baseline factors for remission [28-item DAS (DAS28) < 2.6] at 52 weeks were determined by logistic regression analysis. To confirm whether the associations varied by the level of baseline disease activity, we also assessed the model including the interaction term (each baseline variable × DAS28). RESULTS: In total, 49.3% of the study participants used MTX with TCZ. Even after controlling for the baseline DAS28, shorter disease duration (≤3 year) [odds ratio (OR) 3.58 (95% CI 1.81, 7.07)], less structural damage [Steinbroker stage ≤II, OR 2.33 (95% CI 1.32, 4.12)] and concomitant prednisolone use [OR 0.38 (95% CI 0.21, 0.68)] showed significant predictive values for remission. Concomitant MTX use failed to show a significant association with remission, whereas a significant interaction was observed among concomitant MTX use × DAS28 (P = 0.006). In patients with high baseline disease activity (DAS28 > 5.1), concomitant MTX use was associated with increased odds for remission [adjusted OR for all baseline variables 2.54 (95% CI 1.11, 5.83)], while no association was indicated between them in patients with low to moderate baseline disease activity (DAS28 ≤ 5.1). CONCLUSION: Concomitant MTX use is an important component of TCZ treatment for RApatients with high disease activity.
Authors: M Maldonado-Montoro; M Cañadas-Garre; A González-Utrilla; M Ángel Calleja-Hernández Journal: Pharmacogenomics J Date: 2016-12-13 Impact factor: 3.550
Authors: Javier Narváez; César Díaz-Torné; Berta Magallares; Maria Victoria Hernández; Delia Reina; Héctor Corominas; Raimon Sanmartí; Arturo Rodriguez de la Serna; Josep Maria Llobet; Joan M Nolla Journal: PLoS One Date: 2015-04-01 Impact factor: 3.240
Authors: Cem Gabay; Myriam Riek; Merete Lund Hetland; Ellen-Margrethe Hauge; Karel Pavelka; Matija Tomšič; Helena Canhao; Katerina Chatzidionysiou; Galina Lukina; Dan C Nordström; Elisabeth Lie; Ioan Ancuta; M Victoria Hernández; Piet L M C van Riel; Ronald van Vollenhoven; Tore K Kvien Journal: Ann Rheum Dis Date: 2015-09-15 Impact factor: 19.103
Authors: Mari Kihara; Rebecca Davies; Lianne Kearsley-Fleet; Kath D Watson; Mark Lunt; Deborah P M Symmons; Kimme L Hyrich Journal: Clin Rheumatol Date: 2016-12-02 Impact factor: 2.980
Authors: Leslie R Harrold; Ani John; George W Reed; Tmirah Haselkorn; Chitra Karki; YouFu Li; Jennie Best; Steve Zlotnick; Joel M Kremer; Jeffrey D Greenberg Journal: Rheumatol Ther Date: 2017-09-21
Authors: Soo Min Ahn; Ji Seon Oh; Hyun Mi Heo; Seokchan Hong; Chang-Keun Lee; Bin Yoo; Yong-Gil Kim Journal: J Korean Med Sci Date: 2022-05-02 Impact factor: 2.153